Last reviewed · How we verify
Sulfonylurea/non-sulfonylurea insulin secretagogues
Sulfonylurea/non-sulfonylurea insulin secretagogues is a Insulin secretagogues Small molecule drug developed by Cinnagen. It is currently in Phase 3 development for Type 2 diabetes. Also known as: Sulfonylurea or non-sulfonylurea insulin secretagogues.
Sulfonylurea/non-sulfonylurea insulin secretagogues stimulate insulin release from pancreatic beta cells.
Sulfonylurea/non-sulfonylurea insulin secretagogues stimulate insulin release from pancreatic beta cells. Used for Type 2 diabetes.
At a glance
| Generic name | Sulfonylurea/non-sulfonylurea insulin secretagogues |
|---|---|
| Also known as | Sulfonylurea or non-sulfonylurea insulin secretagogues |
| Sponsor | Cinnagen |
| Drug class | Insulin secretagogues |
| Target | SUR1 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
They work by binding to sulfonylurea receptors on the surface of beta cells, which leads to closure of ATP-sensitive potassium channels and depolarization of the cell membrane. This results in opening of voltage-dependent calcium channels, influx of calcium ions, and subsequent release of insulin from secretory granules.
Approved indications
- Type 2 diabetes
Common side effects
- Hypoglycemia
Key clinical trials
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes (PHASE3)
- A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents
- Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulfonylurea/non-sulfonylurea insulin secretagogues CI brief — competitive landscape report
- Sulfonylurea/non-sulfonylurea insulin secretagogues updates RSS · CI watch RSS
- Cinnagen portfolio CI
Frequently asked questions about Sulfonylurea/non-sulfonylurea insulin secretagogues
What is Sulfonylurea/non-sulfonylurea insulin secretagogues?
How does Sulfonylurea/non-sulfonylurea insulin secretagogues work?
What is Sulfonylurea/non-sulfonylurea insulin secretagogues used for?
Who makes Sulfonylurea/non-sulfonylurea insulin secretagogues?
Is Sulfonylurea/non-sulfonylurea insulin secretagogues also known as anything else?
What drug class is Sulfonylurea/non-sulfonylurea insulin secretagogues in?
What development phase is Sulfonylurea/non-sulfonylurea insulin secretagogues in?
What are the side effects of Sulfonylurea/non-sulfonylurea insulin secretagogues?
What does Sulfonylurea/non-sulfonylurea insulin secretagogues target?
Related
- Drug class: All Insulin secretagogues drugs
- Target: All drugs targeting SUR1
- Manufacturer: Cinnagen — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
- Also known as: Sulfonylurea or non-sulfonylurea insulin secretagogues
- Compare: Sulfonylurea/non-sulfonylurea insulin secretagogues vs similar drugs
- Pricing: Sulfonylurea/non-sulfonylurea insulin secretagogues cost, discount & access